MET Signaling Unveiled as Critical Protective Pathway in Acetaminophen-Induced Acute Liver Failure
A recent study has identified that MET (hepatocyte growth factor receptor) signaling plays a critical protective role in acetaminophen-induced acute liver failure (ALF). This pathway operates through a dual mechanism, both reducing liver damage and accelerating regeneration. The findings, published in The American Journal of Pathology by Elsevier, suggest that targeting MET signaling could offer a novel treatment approach for drug-induced ALF.
The Pervasiveness of Acetaminophen Overdose
Acetaminophen (APAP) is a widely used over-the-counter medication. However, overdose, whether accidental or intentional, is a primary cause of drug-induced liver injury and a significant contributor to ALF in Western countries, representing nearly half of all ALF cases in the United States. Approximately 80,000 APAP overdose cases are reported to hospitals annually, with recovery critically dependent on the liver's regenerative capacity.
Unveiling MET's Role in Toxic Liver Injury and Regeneration
While MET signaling is known to be a central driver of liver regeneration after surgical resections, its specific function during toxic liver injury, characterized by extensive necrosis and inflammation, had remained undefined. This study investigated the impact of hepatocyte-specific MET deletion on liver injury and compensatory regeneration following an APAP overdose in a clinically relevant mouse model.
Lead investigator Bharat Bhushan, PhD, from the University of Pittsburgh School of Medicine, stated that MET deficiency significantly intensified APAP overdose-induced liver injury by enabling toxic stress signals (c-Jun N-terminal kinase; JNK) to affect mitochondria. The absence of MET also severely hindered liver regeneration. He noted that activating survival pathways such as AKT (protein kinase B) helped reduce this damage, indicating MET's essential role in both liver protection and repair after drug-induced overdose. Analysis of human acute liver failure datasets corroborated the clinical relevance of these findings.
Current Therapeutic Limitations for APAP-Induced ALF
Current therapeutic options for acetaminophen-induced ALF are severely limited. N-acetyl cysteine (NAC) is the only approved pharmacological treatment, but its effectiveness is limited in late-presenting patients, who constitute the majority of clinical cases. When NAC therapy is ineffective and ALF progresses rapidly, liver transplantation becomes the only other viable option, constrained by organ availability. Around 30% of APAP-induced ALF cases lead to death.
A Promising Dual Therapeutic Target for Future Treatment
First author Siddhi Jain from the University of Pittsburgh School of Medicine highlighted the urgent need for new therapies that extend beyond the effective time window of NAC. Jain stated that the research is significant because it identifies MET signaling as a key pathway that both restricts liver damage and promotes recovery, presenting a promising dual therapeutic target. It was also noted that therapies designed to boost MET activity may provide a critical lifeline, particularly when existing treatments like NAC are insufficient.